< 1 minute read
Sep. 15, 2021

ABBV-744: An oral in vivo BD2 domain selective BET inhibitor

ABBV-744

BD2 domain selective BET inhibitor orally efficacious in XG w/o platelet, GI tox from SBDD of BD1/2 dual inhibitors Nature, 2020, 578, 306-310 AbbVie, North Chicago, IL

drughunter.com
Drug Hunter Team

ABBV-744 (AbbVie oral in vivo BD2 domain selective BET inhibitor)

Loading...

twitterlinkedinemail

Other molecules you may be interested in